Resources

The resources below can provide further support for healthcare professionals and patients living with pyruvate kinase (PK) deficiency regarding myAgios® Patient Support Services, treatments, and financial support:

Resources for Healthcare Professionals

PYRUKYND Start Form

PYRUKYND® Start Form

Enroll your patients in myAgios.

Annotated PYRUKYND Start Form

Annotated PYRUKYND Start Form

An overview of the myAgios PYRUKYND Start Form.

myAgios HCP Brochure

myAgios HCP Brochure

This brochure outlines all the education and support services provided by myAgios.

PYRUKYND Healthcare Professional Website

PYRUKYND Healthcare Professional Website

Explore the PYRUKYND website to learn more about dosing, efficacy and safety, and how PYRUKYND may help your patients with PK deficiency.

Learn more about PK deficiency

Know PK Deficiency Website

Learn more about PK deficiency and how it affects your patients.

Resources for Your Patients

myAgios Patient Brochure

myAgios Patient Brochure

Helpful information for patients about PK deficiency, PYRUKYND, and myAgios.

fpo

PK Deficiency Patient Brochure

An overview of PYRUKYND treatment for PK deficiency and tools to help patients prepare for their next appointment.

PYRUKYND Patient Website

PYRUKYND Patient Website

Patients can visit the PYRUKYND website to learn all about how it works, how to take it, and how it may help them.

PK Deficiency Community

PYRUKYND patient stories

PYRUKYND patient stories

Hear from patients living with PK deficiency and learn about their experience with PYRUKYND.

PYRUKYND events

PYRUKYND events

Join us for an in-person or online event to learn about PK deficiency and connect with people like you.

Have questions?

Call us at 1-877-77-AGIOS (1-877-772-4467), Mon-Fri, 8 AM to 8 PM ET.

Enroll patients today
INDICATION
IMPORTANT SAFETY INFORMATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Hepatocellular Injury in Another Condition: In patients with another condition treated with mitapivat at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of >5× upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with mitapivat, and these events improved upon treatment discontinuation.

Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is >5× ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.

Adverse Reactions: The most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.

  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.

  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.

  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

INDICATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

Please see full Prescribing Information for PYRUKYND.